journal
MENU ▼
Read by QxMD icon Read
search

Journal of Thoracic Oncology

journal
https://www.readbyqxmd.com/read/28782727/adequacy-of-intra-operative-nodal-staging-during-surgical-resection-of-nsclc-influencing-factors-and-its-relationship-to-survival
#1
Tim Edwards, Haval Balata, Mohamed Elshafi, Philip Foden, Paul Bishop, Eustace Fontaine, Mark Jones, Piotr Krysiak, Kandadai Rammohan, Rajesh Shah, Philip Crosbie, Richard Booton, Matthew Evison
INTRODUCTION: Adequate intra-operative lymph node sampling is a fundamental part of lung cancer surgery but adherence to standards is not well known. This study sought to measure the adequacy of intra-operative lymph node sampling at a regional Thoracic Surgery Centre and a tertiary lung cancer centre in the United Kingdom. METHODS: This retrospective study analysed the pathological reports from NSCLC resections over a four year period 2011-2014. Adequacy of sampling was assessed against IASLC recommendations of at least three mediastinal lymph node stations, station 7 in all patients, stations 5/6 in left upper lobe tumours and station 9 in lower lobe tumours...
August 3, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28782726/validation-of-the-stage-groupings-in-the-8th-edition-of-the-tnm-classification-for-lung-cancer
#2
Sui Xizhao, Jiang Wei, Chen Haiqing, Yang Fan, Wang Jun, Wang Qun
INTRODUCTION: The aim of this study was to validate stage groupings in the 8th edition of the tumor, nodes, metastasis (TNM) classification in an independent Chinese cohort. METHODS: We retrospectively analyzed a total of 3,599 patients with pathological stage IA-IIIA (7th TNM) non-small cell lung cancer (NSCLC) who underwent surgical treatment in two surgical centers in China between 2005 and 2012. All patients were reclassified according to the 8th edition of the TNM classification...
August 3, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28779874/brief-report-met-exon-14-alterations-and-new-resistance-mutations-to-tyrosine-kinase-inhibitors-risk-of-inadequate-detection-with-current-amplicon-based-ngs-panels
#3
Brigitte Poirot, Ludovic Doucet, Shirine Benhenda, Jérôme Champ, Véronique Meignin, Jacqueline Lehmann-Che
INTRODUCTION: Targeted therapies, as tyrosine kinase inhibitors (TKI), have dramatically improved the treatment of lung adenocarcinoma and detection of activating mutations of genes like EGFR or ALK is now mandatory in clinical setting. However, additional targetable alterations are continuously described and force us to adapt our detection methods. We evaluate here the ability of 8 amplicon-based next generation sequencing (NGS) panels to detect the recently described MET exon 14 alterations or new resistance-mutations to TKI...
August 2, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28774862/nivolumab-enhances-the-inflammation-of-the-irradiation-field-in-advanced-non-small-cell-lung-cancer
#4
Hiromi Furuta, Tatsuya Yoshida, Junichi Shimizu, Natsuo Tomita, Yasushi Yatabe, Toyoaki Hida
No abstract text is available yet for this article.
July 31, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28774861/multidisciplinary-tumor-board-decision-making-for-postoperative-radiotherapy-in-thymic-epithelial-tumors-insights-from-the-rythmic-prospective-cohort
#5
Clémence Basse, Sébastien Thureau, Suzanna Bota, Eric Dansin, Pascal-Alexandre Thomas, Eric Pichon, Hervé Lena, Carole Massabeau, Christelle Clement-Duchene, Gilbert Massard, Virginie Westeel, Xavier Quantin, Youssef Oulkhouir, Serge Danhier, Delphine Lerouge, Ronan Tanguy, François Thillays, Cécile Le Pechoux, Bernard Dubray, Luc Thiberville, Benjamin Besse, Nicolas Girard
BACKGROUND: Thymic Epithelial Tumors (TET) are rare intrathoracic malignancies for which surgery represents the mainstay of the treatment. Current practice for postoperative radiotherapy (PORT) is highly variable and there is a lack of prospective, high level evidence. RYTHMIC is the nationwide network for TET in France established in 2012, which prospectively collects data for all TET patients, for whom management is discussed at a national multidisciplinary tumor board (MTB). We assessed whether postoperative radiotherapy (PORT) decisions at the MTB were in accordance with RYTHMIC guidelines, and ultimately implemented in patients...
July 31, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28774860/pulse-dose-erlotinib-and-zuckerguss-improvement-in-egfr-mutant-nsclc
#6
Pareen Mehta, Omid Hamid, Samuel J Klempner
No abstract text is available yet for this article.
July 31, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28757418/obesity-paradox-in-lung-cancer-prognosis-evolving-biological-insights-and-clinical-implications
#7
REVIEW
Xueli Zhang, Yamin Liu, Hua Shao, Xiao Zheng
The survival rate of lung cancer remains low despite the progress of surgery and chemotherapy. With the increasing comorbidity of obesity in lung cancer patients, new challenges emerge in the management of this patient population. A key issue of interest is the prognostic effect of obesity on surgical and chemotherapeutical outcomes in lung cancer patients, which is fueled by the growing observation of survival benefits in overweight or obese patients. This unexpected inverse relation between obesity and lung cancer mortality, called 'obesity paradox', remains poorly understood...
July 27, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28802905/thoracic-oncology-clinical-trial-eligibility-criteria-and-requirements-continue-to-increase-in-number-and-complexity
#8
Sandra Garcia, Ajit Bisen, Jingsheng Yan, Xian-Jin Xie, Suresh Ramalingam, Joan H Schiller, David H Johnson, David E Gerber
BACKGROUND: Eligibility criteria and screening procedures are designed to optimize the scientific yield and maximize the safety of clinical trials. However, they may also heighten trial complexity, hinder enrollment, decrease generalizability, and increase costs. We analyzed the types and number of eligibility criteria and screening procedures among thoracic oncology clinical trials sponsored or endorsed by the Eastern Cooperative Oncology Group (ECOG). METHODS: We identified trials and obtained protocols from the ECOG website...
July 24, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28751247/brief-report-modulation-of-biomarker-expression-by-osimertinib-results-of-the-paired-tumor-biopsy-cohorts-of-the-aura-phase-i-trial
#9
Kenneth S Thress, Vivien Jacobs, Helen K Angell, James Chih-Hsin Yang, Lecia V Sequist, Fiona Blackhall, Wu-Chou Su, Martin Schuler, Jürgen Wolf, Kathryn A Gold, Mireille Cantarini, J Carl Barrett, Pasi A Jänne
INTRODUCTION: Osimertinib is an oral, potent, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) selective for EGFR-TKI and T790M resistance mutations. To enhance understanding of osimertinib's mechanism of action, we aimed to evaluate the modulation of key molecular biomarkers post-osimertinib in paired clinical samples from the Phase I AURA trial. METHODS: Paired tumor biopsies were collected pre-study and following 15±7 days of osimertinib treatment (80 or 160 mg daily)...
July 24, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28751246/concordance-between-comprehensive-cancer-genome-profiling-in-plasma-and-tumor-specimens
#10
Judith N Müller, Markus Falk, Jatin Talwar, Nicole Neemann, Erika Mariotti, Miriam Bertrand, Tobias Zacherle, Sotirios Lakis, Roopika Menon, Christian Gloeckner, Markus Tiemann, Lukas C Heukamp, Roman K Thomas, Frank Griesinger, Johannes M Heuckmann
Detection of somatic genomic alterations in plasma of cancer patients ("liquid biopsy") are increasingly being used in the clinic. However, the concordance of alterations identified in liquid biopsies with those detected in cancer specimens is not routinely being determined. We sought to systematically compare alterations found by a massively parallel sequencing liquid biopsy assay covering 39 genes (NEOliquid) with those identified through routine diagnostic testing in a certified central pathology laboratory in a cohort of non-squamous NSCLC...
July 24, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28751245/comparison-of-22c3-pd-l1-expression-between-surgically-resected-specimens-and-paired-tissue-microarrays-in-non-small-cell-lung-cancer
#11
Chao Li, Cheng Huang, Tony S Mok, Wu Zhuang, Haipeng Xu, Qian Miao, Xirong Fan, Weifeng Zhu, Yunjian Huang, Xiandong Lin, Kan Jiang, Dan Hu, Xiaohui Chen, Peisha Huang, Gen Lin
BACKGROUND: s: It remains unclear what extent intratumoral heterogeneity of PD-L1 expression causes discordances of PD-L1 expression between paired samples. Here, PD-L1 status was compared between whole sections from non-small cell lung cancers and the corresponding tissue microarrays (TMAs) surrogating biopsy specimens. PATIENTS AND METHODS: PD-L1 expression was evaluated by 22C3 IHC assay on 190 archival surgical specimens and matched to the TMA results. The PD-L1 expression was determined by the Tumor Proportion Score (TPS) and classified into TPS <1%, TPS 1 to 49% and TPS ≥50%...
July 24, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28751244/cost-effectiveness-analysis-of-afatinib-versus-gefitinib-for-first-line-treatment-of-advanced-egfr-mutated-advanced-non-small-cell-lung-cancers
#12
Christos Chouaid, Laura Luciani, Katell LeLay, Pascal Do, Jaafar Bennouna, Maurice Perol, Denis Moro-Sibilot, Alain Vergnengre, Gérard de Pouvourville
BACKGROUND: The irreversible ErbB-family-blocker afatinib and the reversible EGFR tyrosine-kinase-inhibitor gefitinib were compared in the multicenter, international, randomized, head-to-head phase-2b LUX-Lung 7 trial for first-line treatment of advanced EGFR-mutation-positive non-small-cell lung cancers (EGFRm+ NSCLCs). Afatinib and gefitinib costs and patients' outcomes in France were assessed. METHODS: A partitioned survival model was designed to assess the cost-effectiveness of afatinib vs...
July 24, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28739441/prognostic-factors-in-completely-resected-node-negative-lung-adenocarcinoma-of-3cm-or-smaller
#13
Jung-Jyh Hung, Yi-Chen Yeh, Yu-Chung Wu, Teh-Ying Chou, Wen-Hu Hsu
INTRODUCTION: The role of adjuvant chemotherapy for patients with stage I non-small cell lung cancer remains unknown. The prognostic value of histological subtypes in resected node-negative small-sized lung adenocarcinoma has not been widely investigated. This study investigated the prognostic factors in patients with node-negative lung adenocarcinoma of 3cm or smaller to find potential candidates for adjuvant chemotherapy. METHODS: A total of 726 patients with completely resected node-negative lung adenocarcinoma of 3cm or smaller were included in the study...
July 21, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28739440/genetic-variation-in-gstp1-lung-function-risk-of-lung-cancer-and-mortality-in-66-000-individuals
#14
Marianne S Nørskov, Morten Dahl, Anne Tybjærg-Hansen
INTRODUCTION: Glutathione-S-transferase (GST) P1 metabolises carcinogens from tobacco smoke in the lung. We tested whether genetically altered GSTP1 activity affects lung function and risk of tobacco-related cancer and mortality in the general population. METHODS: We genotyped 66,069 individuals from the Caucasian general population for two common, functional variants in the GSTP1 gene (Ile105Val and Ala114Val), and recorded lung function, lung cancer, tobacco-related cancer, and death as outcomes...
July 21, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28733269/the-current-role-of-whole-brain-radiation-therapy-in-non-small-cell-lung-cancer-patients
#15
REVIEW
Gokoulakrichenane Loganadane, Lizza Hendriks, Cécile Le Péchoux, Antonin Levy
The incidence of brain metastases (BM) has increased in non-small cell lung cancer (NSCLC) patients as a result of better systemic disease control and advances in imaging modalities. Whole brain radiation therapy (WBRT) has been the mainstay treatment of multiple symptomatic brain metastases for years. A number of recent publications questioned its place in absence of survival and quality of life benefit (QoL) and the possible risk of long-term neurotoxicity. Omission or deferral of WBRT, alongside with strategies consisting of radiosurgery (SRS) or the delivery of systemic therapies alone, are more and more proposed...
July 18, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28729021/ascend-8-a-randomized-phase-1-study-of-ceritinib-450-mg-or-600-mg-taken-with-a-low-fat-meal-versus-750-mg-in-fasted-state-in-patients-with-anaplastic-lymphoma-kinase-alk-rearranged-metastatic-non-small-cell-lung-cancer-nsclc
#16
Byoung Chul Cho, Dong-Wan Kim, Alessandra Bearz, Scott A Laurie, Mark McKeage, Gloria Borra, Keunchil Park, Sang-We Kim, Marwan Ghosn, Andrea Ardizzoni, Evaristo Maiello, Alastair Greystoke, Richard Yu, Karen Osborne, Wen Gu, Jeffrey W Scott, Vanessa Q Passos, Yvonne Y Lau, Anna Wrona
INTRODUCTION: Ceritinib 750 mg fasted is approved for treatment of anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) patients previously treated with crizotinib. Part 1 of ASCEND-8 study determined whether administering ceritinib 450 mg or 600 mg with a low-fat meal may enhance gastrointestinal (GI) tolerability vs 750 mg fasted in ALK+ NSCLC patients while maintaining similar exposure. METHODS: ASCEND-8 is a multicenter, randomized, open-label, phase 1 study...
July 17, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28709937/detection-of-lung-cancer-and-egfr-mutation-by-electronic-nose-system
#17
Dekel Shlomi, Manal Abud, Ori Liran, Jair Bar, Naomi Gai-Mor, Maya Ilouze, Amir Onn, Alon Ben-Nun, Hossam Haick, Nir Peled
BACKGROUND: Early detection of lung cancer (LC) has been well established as a significant key point in patient survival and prognosis. New highly sensitive nanoarray sensors for exhaled Volatile Organic Compounds (VOCs) have been developed and coupled with powerful statistical programs may be used when diseases such as LC are suspected. Detection of genetic aberration mutation by nanoarray sensors is the next target. METHODS: Breath samples were taken from patients who were evaluated for suspicious pulmonary lesions...
July 11, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28694035/assessment-of-the-itmig-statement-on-the-who-histological-classification-and-of-the-8th-tnm-staging-of-thymic-epithelial-tumors-of-a-series-of-188-thymic-epithelial-tumors
#18
Alexandra Meurgey, Nicolas Girard, Claire Merveilleux du Vignaux, Jean-Michel Maury, François Tronc, Françoise Thivolet-Bejui, Lara Chalabreysse
BACKGROUND: Thymic epithelial tumors (TETs) are rare intrathoracic malignancies which are categorized histologically according to the World Health Organization (WHO) classification, recently updated in 2015 based on a consensus statement of ITMIG; at the same time, the standard Masaoka-Koga staging system is intended to be replaced by the 8th edition of the TNM staging classification by the American Joint Committee on Cancer (AJCC)/Union Internationale Contre le Cancer (UICC) consortium...
July 7, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28689043/pooled-systemic-efficacy-and-safety-data-from-the-pivotal-phase-ii-studies-np28673-and-np28761-of-alectinib-in-alk-positive-non-small-cell-lung-cancer
#19
James Chih-Hsin Yang, Sai-Hong Ignatius Ou, Luigi De Petris, Shirish Gadgeel, Leena Gandhi, Dong-Wan Kim, Fabrice Barlesi, Ramaswamy Govindan, Anne-Marie C Dingemans, Lucio Crino, Herve Lena, Sanjay Popat, Jin Seok Ahn, Eric Dansin, Sophie Golding, Walter Bordogna, Bogdana Balas, Peter N Morcos, Ali Zeaiter, Alice T Shaw
INTRODUCTION: Alectinib demonstrated clinical efficacy and an acceptable safety profile in two phase II studies (NP28761 and NP28673). Here we report pooled efficacy and safety data after 15 and 18 months' longer follow-up than the respective primary analyses. MATERIALS AND METHODS: Enrolled patients had ALK-positive NSCLC and had progressed on, or were intolerant to, crizotinib. Patients received oral alectinib 600 mg twice daily. The primary endpoint in both studies was objective response rate (ORR) assessed by an independent review committee (IRC) using Response Evaluation Criteria in Solid Tumors (RECIST v1...
July 5, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28662863/lung-adenocarcinoma-harboring-egfr-t790m-and-in%C3%A2-trans-c797s-responds-to-combination-therapy-of-first-and-third-generation-egfr-tkis-and-shifts-allelic-configuration-at-resistance
#20
Zhen Wang, Jin-Ji Yang, Jie Huang, Jun-Yi Ye, Xu-Chao Zhang, Hai-Yan Tu, Han Han-Zhang, Yi-Long Wu
INTRODUCTION: The efficacy of osimertinib was compromised by the development of resistance mechanisms, such as EGFR C797S. In vitro study proved that cells harboring EGFR C797S in trans with T790M are sensitive to a combination of first- and third-generation EGFR tyrosine kinase inhibitors. However, this has not been reported clinically. METHODS: We performed capture-based sequencing on longitudinal plasma samples obtained at various treatment milestones from a patient with advanced lung adenocarcinoma who was undergoing targeted therapy...
June 27, 2017: Journal of Thoracic Oncology
journal
journal
41363
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"